These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15931384)

  • 21. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
    Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
    Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.
    Williams P; Bouchentouf M; Rafei M; Romieu-Mourez R; Hsieh J; Boivin MN; Yuan S; Forner KA; Birman E; Galipeau J
    J Immunol; 2010 Dec; 185(12):7358-66. PubMed ID: 21076067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
    Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
    J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
    Chang J
    Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of cytotoxic antiviral immunity while considering the 3R principle of animal research.
    Otto L; Zelinskyy G; Schuster M; Dittmer U; Gunzer M
    J Mol Med (Berl); 2018 Apr; 96(3-4):349-360. PubMed ID: 29460050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
    Klug F; Prakash H; Huber PE; Seibel T; Bender N; Halama N; Pfirschke C; Voss RH; Timke C; Umansky L; Klapproth K; Schäkel K; Garbi N; Jäger D; Weitz J; Schmitz-Winnenthal H; Hämmerling GJ; Beckhove P
    Cancer Cell; 2013 Nov; 24(5):589-602. PubMed ID: 24209604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solid tumors "melt" from the inside after successful CD8 T cell attack.
    Blohm U; Potthoff D; van der Kogel AJ; Pircher H
    Eur J Immunol; 2006 Feb; 36(2):468-77. PubMed ID: 16385625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
    Gattinoni L; Klebanoff CA; Palmer DC; Wrzesinski C; Kerstann K; Yu Z; Finkelstein SE; Theoret MR; Rosenberg SA; Restifo NP
    J Clin Invest; 2005 Jun; 115(6):1616-26. PubMed ID: 15931392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.
    Nechushtan H; Pham D; Zhang Y; Morgensztern D; Yi KH; Shin SU; Federoff HJ; Bowers WJ; Tolba KA; Rosenblatt JD
    Cancer Immunol Immunother; 2008 May; 57(5):663-75. PubMed ID: 17952436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local Irradiation Sensitized Tumors to Adoptive T Cell Therapy via Enhancing the Cross-Priming, Homing, and Cytotoxicity of Antigen-Specific CD8 T Cells.
    Lai JZ; Zhu YY; Ruan M; Chen L; Zhang QY
    Front Immunol; 2019; 10():2857. PubMed ID: 31921127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
    Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
    Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.
    Bransi A; Salgado OC; Beffinger M; Milo K; Silina K; Yagita H; Becher B; Knuth A; van den Broek M
    Cancer Immunol Res; 2015 Nov; 3(11):1279-88. PubMed ID: 26141620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.
    Scheffel MJ; Scurti G; Simms P; Garrett-Mayer E; Mehrotra S; Nishimura MI; Voelkel-Johnson C
    Cancer Res; 2016 Oct; 76(20):6006-6016. PubMed ID: 27742673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues.
    Budhu S; Loike JD; Pandolfi A; Han S; Catalano G; Constantinescu A; Clynes R; Silverstein SC
    J Exp Med; 2010 Jan; 207(1):223-35. PubMed ID: 20065066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.